Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …

The growth arrest and DNA damage-inducible (Gadd) 45 proteins have been associated
with numerous cellular mechanisms including cell cycle control, DNA damage sensation …

Objectives: Premature birth, defined as less than 37 weeks gestation, affects approximately
12% of all live births around the world. Advances in neonatal care have resulted in the …

The launch of novel chemotherapeutic agents—in particular, proteasome inhibitors and
immunomodulatory drugs—dramatically changed multiple myeloma (MM) therapy …

Bortezomib-induced peripheral neuropathy (BiPN) occurs in approximately 40% of patients
with multiple myeloma. The induction of severe neuropathy entails the dose reduction or …

Multiple myeloma (MM) is a malignant, incurable neoplastic disease. The currently used
treatment significantly improves the prognosis and extends the survival time of patients …

Methods Global gene and miRNA expression profiles were assessed using genome-wide
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …

Bortezomib is an inhibitor of proteasomes and an anti-cancer drug. Although bortezomib is
considered a safe drug, as confirmed by cytotoxicity assays, recent reports highlighted the …

Non-coding RNAs (ncRNAs) have key roles in the etiology of many illnesses, including heart
failure, myocardial infarction, stroke, and in physiological processes like angiogenesis. In …

Stroke is a main cause of disability and death worldwide, and ischemic stroke accounts for
most stroke cases. Recently, microRNAs (miRNAs) have been verified to play critical roles in …